These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6762087)

  • 1. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
    Thomas MR; Robinson WA; Glode LM; Dantas ME; Koeppler H; Morton N; Sutherland J
    Am J Clin Oncol; 1982 Dec; 5(6):611-22. PubMed ID: 6762087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation.
    Thomas MR; Robinson WA; Mughal TI; Morton N; Glode LM
    Oncology; 1986; 43(5):273-7. PubMed ID: 3531952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial.
    Hartmann DW; Robinson WA; Morton NJ; Mangalik A; Glode LM
    Blut; 1981 Apr; 42(4):209-20. PubMed ID: 7013856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
    Koeppler H; Pflueger KH; Seitz R; Havemann K
    Onkologie; 1989 Dec; 12(6):277-9. PubMed ID: 2696912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation.
    Lazarus HM; Herzig RH; Wolff SN; Phillips GL; Spitzer TR; Fay JW; Herzig GP
    Cancer Treat Rep; 1985 May; 69(5):473-7. PubMed ID: 3891085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
    Tchekmedyian NS; Tait N; Van Echo D; Aisner J
    J Clin Oncol; 1986 Dec; 4(12):1811-8. PubMed ID: 3537218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer.
    Lazarus HM; Herzig RH; Graham-Pole J; Wolff SN; Phillips GL; Strandjord S; Hurd D; Forman W; Gordon EM; Coccia P
    J Clin Oncol; 1983 Jun; 1(6):359-67. PubMed ID: 6366139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
    Shea TC; Antman KH; Eder JP; Elias A; Peters WP; Schryber S; Henner WD; Schoenfeld DA; Schnipper LE; Frei E
    Arch Dermatol; 1988 Jun; 124(6):878-84. PubMed ID: 3288124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
    McElwain TJ; Hedley DW; Burton G; Clink HM; Gordon MY; Jarman M; Juttner CA; Millar JL; Milsted RA; Prentice G; Smith IE; Spence D; Woods M
    Br J Cancer; 1979 Jul; 40(1):72-80. PubMed ID: 383125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
    Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
    J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
    Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
    Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
    Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy with autologous marrow transplantation for malignant melanoma. Case reports and literature review.
    Kessinger A
    J Am Acad Dermatol; 1985 Feb; 12(2 Pt 1):337-43. PubMed ID: 3882786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
    Zulian GB; Selby P; Milan S; Nandi A; Gore M; Forgeson G; Perren TJ; McElwain TJ
    Br J Cancer; 1989 Apr; 59(4):631-5. PubMed ID: 2653400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group.
    Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Frei-Lahr D; Lowder J; Bolwell B; Giannone L; Herzig GP
    J Clin Oncol; 1989 Feb; 7(2):245-9. PubMed ID: 2492594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
    Cornbleet MA; McElwain TJ; Kumar PJ; Filshie J; Selby P; Carter RL; Hedley DW; Clark ML; Millar JL
    Br J Cancer; 1983 Sep; 48(3):329-34. PubMed ID: 6351883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.